A random sample is a sample in which each element of the population has a known (ideally equal) probability of being selected. The objective is to minimize systematic bias and to enable statistical generalization of results to the population. In clinical trials, the concept appears primarily in study planning, statistical inference, and in the interpretation of the generalizability of results.
Basic Principle: Representativeness and Typical Biases
A random sample does not guarantee perfect representativeness, but it is the methodological prerequisite for reducing selection bias. It is particularly important to distinguish it from a convenience sample, in which participants are enrolled because they are “readily available.” In the practice of clinical trials, a true random sample from the entire patient population is rare, because inclusion and exclusion criteria, informed consent processes, recruitment pathways, and site structure strongly influence selection.
Sample quality directly affects external validity: How well can results be transferred to routine care? If the study population is, for example, younger, has fewer comorbidities, or is heavily recruited from specialized centers, effectiveness in everyday practice may differ from the efficacy observed in the trial. Here, supplementary data from real-world evidence can help to better assess transferability.
Random Sample vs. Randomization: Two Different “Random” Concepts
In clinical trials, “random” is often equated with randomization, but methodologically they are different concepts. Randomization randomly allocates enrolled participants to treatment arms and thereby addresses confounding within the study. The random sample, on the other hand, concerns the selection of study participants from a population and addresses the question of whether the study population adequately represents the target population.
A common misconception is to automatically infer a “representative” population from a well-randomized study. Random allocation can ensure internal validity even though recruitment is selective. Therefore, recruitment strategy, inclusion criteria, site mix, and screen failure patterns should be explicitly evaluated and transparently presented in the study report.
Sample Size, Variability, and Statistical Precision
The sample size, together with variability and the expected effect, determines statistical precision. A random sample enables correct interpretation of standard errors, confidence intervals, and p-value-based tests. In practical terms, this means: the larger the sample, the narrower the confidence intervals and the more stable the estimates of mean, median, or proportions. In highly heterogeneous populations, even a large sample can yield wide intervals if the variance is high.
In planning, the required sample size is often derived via a power calculation. This incorporates assumptions about standard deviation, event rate, expected effect size, and dropout rate. For time-to-event endpoints, the number of events often matters, not just the number of enrolled participants. Therefore, a study may have insufficient precision despite high recruitment if fewer events occur than planned.
Practical Implementation: Recruitment, Site Selection, and Quality Control
Even though recruitment in clinical trials rarely corresponds to a random sample, sponsors and CROs can take measures to reduce systematic bias. These include a balanced site mix (university hospitals, specialized practices, and possibly international sites), transparent recruitment channels, and standardized screening processes. Systematic recording of screen failures and dropouts helps to understand selection mechanisms and to account for them later in sensitivity analyses.
Operationally, it is also important that protocol amendments do not inadvertently shift the study population, for example through adjustments to inclusion criteria. Monitoring and central monitoring can detect recruitment and data patterns early, such as implausibly homogeneous baseline characteristics at individual sites or anomalies in documentation. In multicenter studies, it is also relevant whether certain patient groups are enrolled only at a few sites, thereby creating site effects.
Relevance for clinical trials
For the assessment of efficacy and safety, the question of which population the data were collected from is critical. A methodologically sound random sample strengthens generalizability, but is often only achievable to a limited extent in clinical trials. Therefore, the focus in registration trials is on internal validity through randomization and controlled conduct, supplemented by a transparent discussion of external validity. In benefit assessment and health technology assessments, the sampling question can become relevant again when patient populations, care structures, or standards of care vary between countries.
For sponsors and CROs, this means in practice: Already in study planning, it should be clear which target population is to be represented, how recruitment will realistically occur, and what limitations the population has. These limitations should not be glossed over, but actively managed, for example through targeted site selection, adjustments to recruitment strategy, and robust sensitivity analyses in the statistical analysis plan. Additionally, it can be helpful to continuously evaluate recruitment data to check whether the enrolled population shifts over time, for example due to seasonal effects or sites with different catchment areas.
Frequently Asked Questions (FAQ)
Why is a true random sample rare in clinical trials?
Because inclusion and exclusion criteria, informed consent processes, and recruitment pathways influence the selection of participants. This typically results in a selected study population that is not randomly drawn from the overall population.
Is randomization sufficient to generalize results?
Randomization improves internal validity because treatment arms become comparable. For generalizability, an additional assessment is needed of how the study population is composed compared to the target population.
What information helps to better assess the sample?
Useful information includes recruitment channels, screen failures, site mix, baseline characteristics, and dropout rates. This information should be transparently presented in the study report.
Which regulatory and methodological references are particularly relevant for this?
- ICH E9: Basic principles on sample planning, estimation, and inference.
- ICH E6(R3): Requirements for study design, documentation, and data quality.
- Regulation (EU) No 536/2014 (CTR): Framework for clinical trials in the EU and transparency requirements regarding the study population.